5-Fluorouracil, Adriamycin, Cyclophosphamide (FAC) vs. 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) in Metastatic Breast Cancer
Massimo Lopez(Tumori Foundation), Ettore Conti(Tumori Foundation), Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico), Silvia Carpano(Tumori Foundation), Paola Papaldo(Cancer Institute (WIA)), Luigi Di Lauro
Cited by 40
Related Papers
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
|The Lancet|2015|202
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin.
|Journal of Clinical Oncology|1988|168
Lonidamine: Efficacy and safety in clinical trials for thetreatment of solid tumors
|Drugs of today|2003|168
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine
|Annals of Oncology|2010|168
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer
|Breast Cancer Research and Treatment|2006|140